Research Reports

Key takeaways

Svetlana Makhni appointed as Chief Financial Officer and principal financial officer, effective April 16, 2026.

Makhni's compensation includes a $495,000 annual base salary, a $40,000 sign-on bonus, and eligibility for a 40% target annual bonus.

The Board granted Makhni stock options for 800,000 shares with time-based vesting and 100,000 shares subject to milestone achievement.

Allan Reine, M.D. stepped down as principal financial officer but remains Chief Executive Officer and principal executive officer.

Severance terms include 9 months of base salary and 0.75x target bonus for termination without cause, increasing to 12 months and 1.0x after a change in control.

Full analysis

Prime Medicine has appointed Svetlana Makhni as its new Chief Financial Officer, bringing over 20 years of experience in biotechnology CFO roles and investment banking. Her appointment, effective April 16, 2026, follows her tenure as CFO at Marengo Therapeutics and Escient Pharmaceuticals. The compensation package aligns with executive standards, featuring a substantial base salary, sign-on bonus, and significant equity incentives through stock options. The structured severance provisions, including enhanced benefits in the event of a change in control, reflect competitive retention terms. Concurrently, Allan Reine transitions out of the principal financial officer role but maintains his position as CEO, indicating a strategic separation of the CEO and CFO responsibilities.

PRME · Prime Medicine, Inc.

Summary

Key takeaways

Full analysis